Total Payments
$1.2M
2024 Payments
$166,324
Companies
39
Transactions
1,321
Medicare Patients
2,061
Medicare Billing
$251,794
Payment Breakdown by Category
Other$991,810 (84.6%)
Travel$145,309 (12.4%)
Food & Beverage$26,468 (2.3%)
Consulting$7,700 (0.7%)
Research$1,187 (0.1%)
Education$496.79 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $979,610 | 354 | 83.5% |
| Travel and Lodging | $145,309 | 330 | 12.4% |
| Food and Beverage | $26,468 | 609 | 2.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,000 | 2 | 0.7% |
| Consulting Fee | $7,700 | 4 | 0.7% |
| Honoraria | $4,200 | 1 | 0.4% |
| Unspecified | $1,187 | 1 | 0.1% |
| Education | $496.79 | 20 | 0.0% |
Payments by Type
General
$1.2M
1,320 transactions
Research
$1,187
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $582,408 | 632 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $301,991 | 228 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $111,459 | 70 | $0 (2023) |
| Janssen Biotech, Inc. | $106,406 | 89 | $0 (2024) |
| PFIZER INC. | $38,482 | 91 | $0 (2024) |
| Lilly USA, LLC | $13,800 | 7 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $9,748 | 7 | $0 (2017) |
| Takeda Pharmaceuticals America, Inc. | $3,671 | 3 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,322 | 66 | $0 (2024) |
| Eli Lilly and Company | $1,187 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $166,324 | 168 | ABBVIE INC. ($81,105) |
| 2023 | $163,917 | 176 | ABBVIE INC. ($84,394) |
| 2022 | $161,008 | 182 | ABBVIE INC. ($59,905) |
| 2021 | $92,914 | 141 | AbbVie Inc. ($65,222) |
| 2020 | $67,950 | 74 | AbbVie Inc. ($34,012) |
| 2019 | $155,436 | 198 | AbbVie, Inc. ($84,652) |
| 2018 | $164,873 | 173 | AbbVie, Inc. ($83,811) |
| 2017 | $200,550 | 209 | Janssen Scientific Affairs, LLC ($96,339) |
All Payment Transactions
1,321 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $526.24 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $122.65 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Sandoz Inc. | HYRIMOZ (Biological) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $650.06 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $143.82 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $866.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.84 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,275.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $115.62 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $677.88 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $1,187 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 472 | 538 | $282,699 | $53,193 |
| 2022 | 11 | 451 | 538 | $284,311 | $53,982 |
| 2021 | 12 | 602 | 824 | $357,466 | $84,077 |
| 2020 | 14 | 536 | 751 | $271,648 | $60,542 |
Total Patients
2,061
Total Services
2,651
Medicare Billing
$251,794
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 94 | $51,418 | $10,619 | 20.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 82 | 82 | $65,026 | $10,007 | 15.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 33 | 33 | $31,119 | $6,777 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 90 | $35,280 | $6,342 | 18.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 80 | 81 | $48,600 | $6,251 | 12.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $12,348 | $2,863 | 23.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 27 | $8,127 | $2,526 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 41 | $11,316 | $2,505 | 22.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 38 | $7,980 | $2,363 | 29.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $6,400 | $1,637 | 25.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $5,085 | $1,303 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 85 | 125 | $68,375 | $14,983 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 104 | $40,768 | $8,209 | 20.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 66 | 68 | $53,924 | $7,062 | 13.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 28 | 29 | $27,347 | $5,867 | 21.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 66 | 67 | $40,200 | $5,118 | 12.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $13,380 | $2,845 | 21.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 42 | $8,820 | $2,380 | 27.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $8,820 | $2,345 | 26.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 27 | $8,127 | $2,178 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 26 | 27 | $7,452 | $1,553 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $7,098 | $1,442 | 20.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 97 | 154 | $77,613 | $20,904 | 26.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 134 | $49,018 | $12,520 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 95 | 183 | $38,430 | $10,610 | 27.6% |
About Dr. Nitin Gupta, M.D
Dr. Nitin Gupta, M.D is a Internal Medicine healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013113364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nitin Gupta, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $166,324 received in 2024. These payments were reported across 1,321 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($979,610).
As a Medicare-enrolled provider, Gupta has provided services to 2,061 Medicare beneficiaries, totaling 2,651 services with total Medicare billing of $251,794. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology, Gastroenterology
- Location Atlanta, GA
- Active Since 06/25/2007
- Last Updated 10/03/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1013113364
Products in Payments
- STELARA (Biological) $345,367
- Humira (Biological) $196,950
- SKYRIZI (Biological) $124,495
- ZEPOSIA (Drug) $111,885
- RINVOQ (Biological) $93,609
- HUMIRA (Biological) $76,413
- TREMFYA (Drug) $62,922
- XELJANZ (Drug) $31,551
- OMVOH (Drug) $13,800
- APRISO (Drug) $9,674
- VELSIPITY (Drug) $6,919
- Entyvio (Biological) $4,215
- ENTYVIO (Biological) $587.36
- XIFAXAN (Drug) $512.75
- DIFICID (Drug) $219.01
- ZENPEP (Drug) $187.42
- INJECTAFER (Drug) $168.95
- Sucraid (Drug) $146.77
- VIBERZI (Drug) $110.81
- REMICADE (Biological) $107.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Atlanta
Dr. Zandraetta Tims-Cook, Md, Mph, MD, MPH
Internal Medicine — Payments: $648,799
Internal Medicine $648,799
Brian Pearlman, Md, MD
Internal Medicine — Payments: $588,483
Internal Medicine $588,483
Tracey Henry
Internal Medicine — Payments: $304,663
Internal Medicine $304,663
Michael Lloyd, Md, MD
Internal Medicine — Payments: $276,236
Internal Medicine $276,236
Mr. Robert Springer, M.d, M.D
Internal Medicine — Payments: $243,195
Internal Medicine $243,195
Dr. Ebon Bourne, M.d, M.D
Internal Medicine — Payments: $196,841
Internal Medicine $196,841